STAT3 and non-small cell lung carcinoma: Among the 17 main targets of Aspiletreins in NSCLC, the top 5 potential targets, including STAT3, VEGFA, HSP90AA1, FGF2, and IL-2, were investigated for possible interaction with Aspiletreins.